{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T01:59:00Z","timestamp":1779242340601,"version":"3.51.4"},"reference-count":134,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2008,2,15]],"date-time":"2008-02-15T00:00:00Z","timestamp":1203033600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["American J Hematol"],"published-print":{"date-parts":[[2008,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The recent discovery of <jats:italic>JAK2<\/jats:italic> and\/or <jats:italic>MPL<\/jats:italic> mutations in polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF) has had a major impact on how we diagnose and treat these disorders. For instance, the presence of a <jats:italic>JAK2<\/jats:italic> mutation is now considered <jats:italic>conditio sine qua non<\/jats:italic> for the diagnosis of PV and the World Health Organization classification system has recently revised its diagnostic criteria for PV, ET, and PMF to include <jats:italic>JAK2<\/jats:italic> and <jats:italic>MPL<\/jats:italic> mutations as clonal markers. From the standpoint of treatment, JAK\u2010STAT is now identified as a legitimate target pathway for drug development in myeloproliferative neoplasms. Herein, I will first outline my views regarding current management in ET, PV, and PMF and then discuss emerging data on preclinical and clinical activity of anti\u2010JAK2 small molecule drugs. Am. J. Hematol., 2008. \u00a9 2008 Wiley\u2010Liss, Inc.<\/jats:p>","DOI":"10.1002\/ajh.21183","type":"journal-article","created":{"date-parts":[[2008,2,15]],"date-time":"2008-02-15T19:16:43Z","timestamp":1203103003000},"page":"491-497","source":"Crossref","is-referenced-by-count":65,"title":["Essential thrombocythemia, polycythemia vera, and myelofibrosis: Current management and the prospect of targeted therapy"],"prefix":"10.1002","volume":"83","author":[{"given":"Ayalew","family":"Tefferi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2008,4,21]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404955"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-04-083501"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2210"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa065202"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404810"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404086"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2005.05743.x"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)71142-9"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature03546"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051113"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2005.03.023"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm0596-561"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa062867"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-02-004325"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404948"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404500"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2007.06674.x"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.4065\/81.2.159"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa035572"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199504273321704"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.0954-6820.1962.tb07186.x"},{"key":"e_1_2_1_23_2","first-page":"166","volume-title":"Polycythemia Vera and the Myeloproliferative Disorders","author":"Berk PD","year":"1995"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22630"},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-12-038968"},{"key":"e_1_2_1_26_2","first-page":"215","article-title":"Practice guidelines for the therapy of essential thrombocythemia. A statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation","volume":"89","author":"Barbui T","year":"2004","journal-title":"Haematologica"},{"key":"e_1_2_1_27_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMe058093"},{"key":"e_1_2_1_28_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1997.d01-2127.x"},{"key":"e_1_2_1_29_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2000.02188.x"},{"key":"e_1_2_1_30_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-01-0135"},{"key":"e_1_2_1_31_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V82.6.1749.1749"},{"key":"e_1_2_1_32_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-05-025544"},{"key":"e_1_2_1_33_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2006.06430.x"},{"key":"e_1_2_1_34_2","doi-asserted-by":"publisher","DOI":"10.4065\/78.2.174"},{"key":"e_1_2_1_35_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1990.8.3.556"},{"key":"e_1_2_1_36_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-09-046342"},{"key":"e_1_2_1_37_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-976165"},{"key":"e_1_2_1_38_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2004.05277.x"},{"key":"e_1_2_1_39_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-08-042515"},{"key":"e_1_2_1_40_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-01-066985"},{"key":"e_1_2_1_41_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404724"},{"key":"e_1_2_1_42_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22663"},{"key":"e_1_2_1_43_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-12-064287"},{"key":"e_1_2_1_44_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1986.tb07497.x"},{"key":"e_1_2_1_45_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa043800"},{"key":"e_1_2_1_46_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V90.9.3370"},{"key":"e_1_2_1_47_2","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1981.150"},{"key":"e_1_2_1_48_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2003.04542.x"},{"key":"e_1_2_1_49_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.thj.6200250"},{"key":"e_1_2_1_50_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.0007-1048.2002.03367.x"},{"key":"e_1_2_1_51_2","first-page":"1011","article-title":"Efficacy of pipobroman in the treatment of polycythemia vera: Long\u2010term results in 163 patients","volume":"85","author":"Passamonti F","year":"2000","journal-title":"Haematologica"},{"key":"e_1_2_1_52_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1985.tb02880.x"},{"key":"e_1_2_1_53_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1987.tb06150.x"},{"key":"e_1_2_1_54_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404743"},{"key":"e_1_2_1_55_2","first-page":"40","article-title":"Interferon alfa: Effects of long\u2010term treatment for polycythemia vera","volume":"34","author":"Silver RT","year":"1997","journal-title":"Semin Hematol"},{"key":"e_1_2_1_56_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-996123"},{"key":"e_1_2_1_57_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22026"},{"key":"e_1_2_1_58_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21900"},{"key":"e_1_2_1_59_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-03-009860"},{"key":"e_1_2_1_60_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-09-3917"},{"key":"e_1_2_1_61_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-09-3426"},{"key":"e_1_2_1_62_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0609.2001.00367.x"},{"key":"e_1_2_1_63_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-01-071068"},{"key":"e_1_2_1_64_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2006-942763"},{"key":"e_1_2_1_65_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1521-6926(03)00019-7"},{"key":"e_1_2_1_66_2","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V110.11.554.554","article-title":"Erythropoiesis stimulating agents and the risk of leukemic transformation in primary myelofibrosis","volume":"110","author":"Huang J","year":"2007","journal-title":"Blood"},{"key":"e_1_2_1_67_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1997.782714.x"},{"key":"e_1_2_1_68_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2006.12.025"},{"key":"e_1_2_1_69_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21644"},{"key":"e_1_2_1_70_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200004273421706"},{"key":"e_1_2_1_71_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21645"},{"key":"e_1_2_1_72_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1998.00833.x"},{"key":"e_1_2_1_73_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V88.3.1013.1013"},{"key":"e_1_2_1_74_2","first-page":"2831","article-title":"Allogeneic stem cell transplantation for agnogenic myeloid metaplasia: A European group for blood and marrow transplantation, Societe Francaise de Greffe de Moelle, Gruppo Italiano per il Trapianto del Midollo Osseo, and Fred Hutchinson Cancer Research Center collaborative study","volume":"93","author":"Guardiola P","year":"1999","journal-title":"Blood"},{"key":"e_1_2_1_75_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200008313430913"},{"key":"e_1_2_1_76_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-06-1856"},{"key":"e_1_2_1_77_2","first-page":"683","article-title":"Dose\u2010reduced conditioning followed by allogeneic stem cell transplantation in patients with myelofibrosis. Results from a multicenter prospective trial of the chronic leukemia working party of the european group for blood and marrow transplantation (EBMT)","volume":"110","author":"Kroeger N","year":"2007","journal-title":"ASH Annu Meet Abstr"},{"key":"e_1_2_1_78_2","first-page":"126","volume-title":"Agnogenic myeloid metaplasia","author":"Silverstein MN","year":"1975"},{"key":"e_1_2_1_79_2","first-page":"616","article-title":"rHuEpo for the treatment of anemia in myelofibrosis with myeloid metaplasia. Experience in 6 patients and meta\u2010analytical approach","volume":"83","author":"Rodriguez JN","year":"1998","journal-title":"Haematologica"},{"key":"e_1_2_1_80_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2006.06142.x"},{"key":"e_1_2_1_81_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2004.05229.x"},{"key":"e_1_2_1_82_2","first-page":"595","article-title":"Danazol treatment of idiopathic myelofibrosis with severe anemia","volume":"85","author":"Cervantes F","year":"2000","journal-title":"Haematologica"},{"key":"e_1_2_1_83_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2005.05524.x"},{"key":"e_1_2_1_84_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.12.4007"},{"key":"e_1_2_1_85_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2002.03443.x"},{"key":"e_1_2_1_86_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.08.160"},{"key":"e_1_2_1_87_2","doi-asserted-by":"publisher","DOI":"10.4065\/79.7.883"},{"key":"e_1_2_1_88_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-09-2928"},{"key":"e_1_2_1_89_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-02-004572"},{"key":"e_1_2_1_90_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404711"},{"key":"e_1_2_1_91_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.1988.tb00212.x"},{"key":"e_1_2_1_92_2","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/j.1742-1241.2002.tb11263.x","article-title":"Myelofibrosis: Response to busulfan after hydroxyurea failure","volume":"56","author":"Naqvi T","year":"2002","journal-title":"Int J Clin Pract"},{"key":"e_1_2_1_93_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.0007-1048.2001.03331.x"},{"key":"e_1_2_1_94_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1997.3843198.x"},{"key":"e_1_2_1_95_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V97.6.1896"},{"key":"e_1_2_1_96_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V95.7.2226"},{"key":"e_1_2_1_97_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22021"},{"key":"e_1_2_1_98_2","first-page":"747a","article-title":"Antemortem presentation and management of non\u2010hepatosplenic extramedullary hematopoiesis in myelofibrosis with myeloid metaplasia","volume":"96","author":"Houck WA","year":"2000","journal-title":"Blood"},{"key":"e_1_2_1_99_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.120.3.801"},{"key":"e_1_2_1_100_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2002.03695.x"},{"key":"e_1_2_1_101_2","doi-asserted-by":"publisher","DOI":"10.4065\/70.12.1161"},{"key":"e_1_2_1_102_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0030270"},{"key":"e_1_2_1_103_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404206"},{"key":"e_1_2_1_104_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404405"},{"key":"e_1_2_1_105_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404379"},{"key":"e_1_2_1_106_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-04-018879"},{"key":"e_1_2_1_107_2","first-page":"2546","article-title":"Detection of three different MPLW515 Mutations in 10.1% of all JAK2 V617 unmutated ET and 9.3% of all JAK2 V617F unmutated OMF: A study of 387 patients","volume":"110","author":"Schnittger S","year":"2007","journal-title":"ASH Annu Meet Abstr"},{"key":"e_1_2_1_108_2","first-page":"677","article-title":"Clinical significance of MPL mutations in essential thrombocythemia: Analysis of the PT\u20101 Cohort","volume":"110","author":"Beer P","year":"2007","journal-title":"ASH Annu Meet Abstr"},{"key":"e_1_2_1_109_2","first-page":"678","article-title":"The clinical phenotype of patients with essential thrombocythemia harboring MPL 515W>L\/K mutation","volume":"110","author":"Vannucchi AM","year":"2007","journal-title":"ASH Annu Meet Abstr"},{"key":"e_1_2_1_110_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2007.06565.x"},{"key":"e_1_2_1_111_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404854"},{"key":"e_1_2_1_112_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-10-054940"},{"key":"e_1_2_1_113_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-07-101576"},{"key":"e_1_2_1_114_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2005.05764.x"},{"key":"e_1_2_1_115_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403902"},{"key":"e_1_2_1_116_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)67785-9"},{"key":"e_1_2_1_117_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2005.05776.x"},{"key":"e_1_2_1_118_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-07-099184"},{"key":"e_1_2_1_119_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2006.04.008"},{"key":"e_1_2_1_120_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-08-3395"},{"key":"e_1_2_1_121_2","article-title":"Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia\u2010free survival","author":"Tefferi A","journal-title":"Leukemia"},{"key":"e_1_2_1_122_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404750"},{"key":"e_1_2_1_123_2","first-page":"3541","article-title":"Primary cell experiments with TG101348, a JAK2\u2010selective inhibitor, in the presence of myeloproliferative disorder\u2010associated JAK2V617F, MPLW515L\/K, and JAK2 Exon 12 mutations","volume":"110","author":"Lasho TL","year":"2007","journal-title":"ASH Annu Meet Abstr"},{"key":"e_1_2_1_124_2","first-page":"556","article-title":"Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F\u2010induced polycythemia vera","volume":"110","author":"Wernig G","year":"2007","journal-title":"ASH Annu Meet Abstr"},{"key":"e_1_2_1_125_2","first-page":"1526","article-title":"Selective inhibition of JAK2 driven erythroid differentiation of polycythemia vera progenitors","volume":"110","author":"Geron I","year":"2007","journal-title":"ASH Annu Meet Abstr"},{"key":"e_1_2_1_126_2","first-page":"557","article-title":"A selective and potent oral inhibitor of the JAK2 tyrosine kinase reverses polycythemia and leukocytosis induced by JAK2 V617F in a mouse model","volume":"110","author":"Zaleskas VM","year":"2007","journal-title":"ASH Annu Meet Abstr"},{"key":"e_1_2_1_127_2","article-title":"The histone deacetylase inhibitor ITF2357 selectively targets cells bearing mutated JAK2(V617F)","author":"Guerini V","year":"2007","journal-title":"Leukemia"},{"key":"e_1_2_1_128_2","first-page":"558","article-title":"INCB018424, an oral, selective JAK2 inhibitor, shows significant clinical activity in a phase I\/II study in patients with primary myelofibrosis (PMF) and post polycythemia vera\/essential thrombocythemia myelofibrosis (Post\u2010PV\/ET MF)","volume":"110","author":"Verstovsek S","year":"2007","journal-title":"ASH Annu Meet Abstr"},{"key":"e_1_2_1_129_2","first-page":"553","article-title":"A phase I study of XL019, a selective JAK2 inhibitor, in patients with primary myelofibrosis and post\u2010polycythemia vera\/essential thrombocythemia myelofibrosis","volume":"110","author":"Verstovsek S","year":"2007","journal-title":"ASH Annu Meet Abstr"},{"key":"e_1_2_1_130_2","article-title":"Lestaurtinib (CEP701)is a JAK2 inhibitor that suppresses JAK2\/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders","author":"Hexner EO","journal-title":"Blood"},{"key":"e_1_2_1_131_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.C600277200"},{"key":"e_1_2_1_132_2","first-page":"3543","article-title":"Phase II Study of CEP701, an orally available JAK2 inhibitor, in patients with primary myelofibrosis and post polycythemia vera\/essential thrombocythemia myelofibrosis","volume":"110","author":"Verstovsek S","year":"2007","journal-title":"ASH Annu Meet Abstr"},{"key":"e_1_2_1_133_2","article-title":"20+ years without leukemic or fibrotic transformation in essential thrombocythemia or polycythemia vera: Predictors at diagnosis","author":"Tefferi A","journal-title":"Eur J Haematol"},{"key":"e_1_2_1_134_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.moh.0000208469.48614.2e"},{"key":"e_1_2_1_135_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404473"}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fajh.21183","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.21183","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,15]],"date-time":"2023-11-15T17:25:13Z","timestamp":1700069113000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.21183"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,4,21]]},"references-count":134,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2008,6]]}},"alternative-id":["10.1002\/ajh.21183"],"URL":"https:\/\/doi.org\/10.1002\/ajh.21183","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"value":"0361-8609","type":"print"},{"value":"1096-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,4,21]]}}}